Michelle Yanez - 04 May 2026 Form 4 Insider Report for Inhibitor Therapeutics, Inc. (INTI)

Reporting relationship: Director
Issuer ticker: INTI
Reported as of: 04 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Aug 2026, 12:19:04 UTC
Prior SEC filing: 19 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Michelle Yanez

Key filing fact

Michelle Yanez filed Form 4 for Inhibitor Therapeutics, Inc. (INTI) on 04 Aug 2026.

Key facts

This page summarizes Michelle Yanez's Form 4 filing for Inhibitor Therapeutics, Inc. (INTI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Aug 2026, 12:19.

Change

Previous filing in this sequence was filed on 19 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001958023 Primary reporting owner

Yanez Michelle

Relationship: Director
Address: C/O INHIBITOR THERAPEUTICS, INC.,, 3014 WEST PALMIRA AVE SUITE 302, TAMPA
Signature: /s/ Michelle Yanez
Signature date: 04 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INTI transaction

Common Stock

Award

Transaction value
Shares: +50,000
Change %: +4.3%
Price: $0.000000^*
Shares after: 1,221,271
Date: 04 May 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval.